Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Acquired by Janus Henderson Group PLC

Janus Henderson Group PLC increased its position in Scholar Rock Holding Co. (NASDAQ:SRRK) by 5,951.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 849,178 shares of the company’s stock after buying an additional 835,145 shares during the period. Janus Henderson Group PLC owned about 0.91% of Scholar Rock worth $36,731,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Scholar Rock by 17.6% in the fourth quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company’s stock valued at $205,013,000 after buying an additional 708,817 shares during the last quarter. Principal Financial Group Inc. acquired a new position in Scholar Rock during the fourth quarter worth approximately $274,000. Rhumbline Advisers increased its position in Scholar Rock by 13.2% during the fourth quarter. Rhumbline Advisers now owns 113,261 shares of the company’s stock worth $4,895,000 after purchasing an additional 13,247 shares during the last quarter. Blackstone Inc. acquired a new position in Scholar Rock during the fourth quarter worth approximately $910,000. Finally, Raymond James Financial Inc. acquired a new position in Scholar Rock during the fourth quarter worth approximately $2,625,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Wedbush reaffirmed an “outperform” rating and set a $50.00 price target on shares of Scholar Rock in a research report on Wednesday. Six analysts have rated the stock with a buy rating, According to MarketBeat, Scholar Rock presently has an average rating of “Buy” and a consensus price target of $42.67.

Insider Buying and Selling

In related news, insider Mo Qatanani sold 68,510 shares of the business’s stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $37.40, for a total transaction of $2,562,274.00. Following the transaction, the insider now directly owns 111,084 shares of the company’s stock, valued at approximately $4,154,541.60. The trade was a 38.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Edward H. Myles sold 7,809 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $36.83, for a total value of $287,605.47. Following the completion of the transaction, the chief financial officer now owns 140,740 shares of the company’s stock, valued at approximately $5,183,454.20. This represents a 5.26% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 255,231 shares of company stock valued at $9,220,236. Company insiders own 13.30% of the company’s stock.

Scholar Rock Stock Performance

Shares of SRRK stock opened at $30.54 on Thursday. Scholar Rock Holding Co. has a one year low of $6.76 and a one year high of $46.98. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. The company has a 50 day moving average price of $31.35 and a 200 day moving average price of $35.87. The firm has a market capitalization of $2.90 billion, a price-to-earnings ratio of -13.00 and a beta of 0.37.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.04). Sell-side analysts anticipate that Scholar Rock Holding Co. will post -2.42 EPS for the current year.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.